{
    "Trade/Device Name(s)": [
        "Albumin BCG2"
    ],
    "Submitter Information": "Abbott Ireland Diagnostics Division",
    "510(k) Number": "K203248",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981758"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIX"
    ],
    "Summary Letter Date": "August 30, 2021",
    "Summary Letter Received Date": "August 31, 2021",
    "Submission Date": "November 15, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1035"
    ],
    "Regulation Name(s)": [
        "Albumin Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Albumin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Serum separator tube",
        "Dipotassium EDTA tube",
        "Lithium heparin tube",
        "Lithium heparin separator tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c System"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetric (Bromocresol Green)"
    ],
    "Methodologies": [
        "Colorimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Albumin BCG2 colorimetric assay for albumin quantitation in serum or plasma using ARCHITECT c System",
    "Indications for Use Summary": "Used for the quantitation of albumin in human serum or plasma on the ARCHITECT c System as an aid in the diagnosis and treatment of diseases involving primarily the liver or kidneys",
    "fda_folder": "Clinical Chemistry"
}